Through this study, the investigators are to prove that Cilostazol effectively prevent progression of intima-medial thickness in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects. The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the progression of intima-medial thickness compared to aspirin in the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
800
Cilostazol 100mg bid
Probucol 250mg bid
Aspirin 100mg qd
same shape and size of active cilostazol
same size and shape of active aspirin 100mg
ultrasound measured IMT of both common carotid arteries
mean carotid IMT progression
Annualized rate of change in mean common carotid intimal-medial thickness
Time frame: one year
maximum carotid IMT progression
annualized rate of change in maximal carotid intimal-medial thickness
Time frame: one year
carotid plaque score
annualized change of carotid plaque score
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.